This week, Johnson & Johnson paused a clinical trial of its COVID-19 vaccine candidate because one of its 60,000 participants is experiencing an "unexplained illness."
This comes after AstraZeneca briefly paused a trial just last month after one of its 30,000 subjects had experienced an illness. That trial resumed once an investigation revealed that the illness was unrelated to the test…